Deferasirox

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Pilot Study for Patients With Poor Response to Deferasirox

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

Treatment of Iron Overload Requiring Chelation Therapy

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65